Your browser doesn't support javascript.
The age again in the eye of the COVID-19 storm: evidence-based decision making.
Martín, María C; Jurado, Aurora; Abad-Molina, Cristina; Orduña, Antonio; Yarce, Oscar; Navas, Ana M; Cunill, Vanesa; Escobar, Danilo; Boix, Francisco; Burillo-Sanz, Sergio; Vegas-Sánchez, María C; Jiménez-de Las Pozas, Yesenia; Melero, Josefa; Aguilar, Marta; Sobieschi, Oana Irina; López-Hoyos, Marcos; Ocejo-Vinyals, Gonzalo; San Segundo, David; Almeida, Delia; Medina, Silvia; Fernández, Luis; Vergara, Esther; Quirant, Bibiana; Martínez-Cáceres, Eva; Boiges, Marc; Alonso, Marta; Esparcia-Pinedo, Laura; López-Sanz, Celia; Muñoz-Vico, Javier; López-Palmero, Serafín; Trujillo, Antonio; Álvarez, Paula; Prada, Álvaro; Monzón, David; Ontañón, Jesús; Marco, Francisco M; Mora, Sergio; Rojo, Ricardo; González-Martínez, Gema; Martínez-Saavedra, María T; Gil-Herrera, Juana; Cantenys-Molina, Sergi; Hernández, Manuel; Perurena-Prieto, Janire; Rodríguez-Bayona, Beatriz; Martínez, Alba; Ocaña, Esther; Molina, Juan.
  • Martín MC; Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain.
  • Jurado A; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain. aurora.jurado.sspa@juntadeandalucia.es.
  • Abad-Molina C; Department of Microbiology and Immunology, Hospital Clínico Universitario, Valladolid, Spain.
  • Orduña A; Department of Microbiology and Immunology, Hospital Clínico Universitario, Valladolid, Spain.
  • Yarce O; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
  • Navas AM; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
  • Cunill V; Department of Immunology, Hospital Universitario Son Espases-Human Immunopathology Research Laboratory, Institut d'Investigació Sanitària de les Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Escobar D; Department of Immunology, Hospital Universitario Son Espases-Human Immunopathology Research Laboratory, Institut d'Investigació Sanitària de les Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Boix F; Department of Immunology, Hospital Clínico Universitario, Salamanca, Spain.
  • Burillo-Sanz S; Department of Immunology, Hospital Clínico Universitario, Salamanca, Spain.
  • Vegas-Sánchez MC; Department of Immunology, Fundación Jiménez Díaz, Madrid, Spain.
  • Jiménez-de Las Pozas Y; Department of Immunology, Fundación Jiménez Díaz, Madrid, Spain.
  • Melero J; Department of Immunology, Hospital Universitario de Badajoz, Badajoz, Spain.
  • Aguilar M; Department of Immunology, Hospital Universitario de Badajoz, Badajoz, Spain.
  • Sobieschi OI; Department of Immunology, Hospital Universitario de Badajoz, Badajoz, Spain.
  • López-Hoyos M; Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Ocejo-Vinyals G; Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • San Segundo D; Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Almeida D; Laboratory of Immunology, Complejo Hospitalario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
  • Medina S; Laboratory of Immunology, Complejo Hospitalario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
  • Fernández L; Laboratoy of Immunology and Genetics, Hospital San Pedro de Alcántara, Cáceres, Spain.
  • Vergara E; Laboratoy of Immunology and Genetics, Hospital San Pedro de Alcántara, Cáceres, Spain.
  • Quirant B; Department of Immunology, Hospital Germans Trias i Pujols, Barcelona, Spain.
  • Martínez-Cáceres E; Department of Immunology, Hospital Germans Trias i Pujols, Barcelona, Spain.
  • Boiges M; Department of Immunology, Hospital Germans Trias i Pujols, Barcelona, Spain.
  • Alonso M; Department of Immunology, Hospital de Cruces, Baracaldo, Spain.
  • Esparcia-Pinedo L; Department of Immunology, Hospital Universitario La Princesa, Madrid, Spain.
  • López-Sanz C; Department of Immunology, Hospital Universitario La Princesa, Madrid, Spain.
  • Muñoz-Vico J; Department of Immunology, Hospital Torrecárdenas, Almería, Spain.
  • López-Palmero S; Department of Immunology, Hospital Torrecárdenas, Almería, Spain.
  • Trujillo A; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
  • Álvarez P; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
  • Prada Á; Department of Immunology, Hospital de Donostia, San Sebastián, Spain.
  • Monzón D; Department of Immunology, Hospital de Donostia, San Sebastián, Spain.
  • Ontañón J; Unit of Immunology, Hospital General Universitario, Albacete, Spain.
  • Marco FM; Laboratory Unit, Hospital General, Alicante, Spain.
  • Mora S; Laboratory Unit, Hospital General, Alicante, Spain.
  • Rojo R; Department of Immunology, Complejo Hospitalario, La Coruña, Spain.
  • González-Martínez G; Unit of Immunology, Hospital Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain.
  • Martínez-Saavedra MT; Unit of Immunology, Hospital Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain.
  • Gil-Herrera J; Department of Immunology, Hospital General Universitario e Instituto de Investigación Sanitaria, "Gregorio Marañón", Madrid, Spain.
  • Cantenys-Molina S; Department of Immunology, Hospital General Universitario e Instituto de Investigación Sanitaria, "Gregorio Marañón", Madrid, Spain.
  • Hernández M; Department of Immunology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Perurena-Prieto J; Department of Immunology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Rodríguez-Bayona B; Laboratory Unit, Hospital Juan Ramón Jiménez, Huelva, Spain.
  • Martínez A; Laboratory Unit, Complejo Hospitalario, Jaén, Spain.
  • Ocaña E; Laboratory Unit, Complejo Hospitalario, Jaén, Spain.
  • Molina J; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
Immun Ageing ; 18(1): 24, 2021 May 20.
Artículo en Inglés | MEDLINE | ID: covidwho-1238723
ABSTRACT

BACKGROUND:

One hundred fifty million contagions, more than 3 million deaths and little more than 1 year of COVID-19 have changed our lives and our health management systems forever. Ageing is known to be one of the significant determinants for COVID-19 severity. Two main reasons underlie this immunosenescence and age correlation with main COVID-19 comorbidities such as hypertension or dyslipidaemia. This study has two aims. The first is to obtain cut-off points for laboratory parameters that can help us in clinical decision-making. The second one is to analyse the effect of pandemic lockdown on epidemiological, clinical, and laboratory parameters concerning the severity of the COVID-19. For these purposes, 257 of SARSCoV2 inpatients during pandemic confinement were included in this study. Moreover, 584 case records from a previously analysed series, were compared with the present study data.

RESULTS:

Concerning the characteristics of lockdown series, mild cases accounted for 14.4, 54.1% were moderate and 31.5%, severe. There were 32.5% of home contagions, 26.3% community transmissions, 22.5% nursing home contagions, and 8.8% corresponding to frontline worker contagions regarding epidemiological features. Age > 60 and male sex are hereby confirmed as severity determinants. Equally, higher severity was significantly associated with higher IL6, CRP, ferritin, LDH, and leukocyte counts, and a lower percentage of lymphocyte, CD4 and CD8 count. Comparing this cohort with a previous 584-cases series, mild cases were less than those analysed in the first moment of the pandemic and dyslipidaemia became more frequent than before. IL-6, CRP and LDH values above 69 pg/mL, 97 mg/L and 328 U/L respectively, as well as a CD4 T-cell count below 535 cells/µL, were the best cut-offs predicting severity since these parameters offered reliable areas under the curve.

CONCLUSION:

Age and sex together with selected laboratory parameters on admission can help us predict COVID-19 severity and, therefore, make clinical and resource management decisions. Demographic features associated with lockdown might affect the homogeneity of the data and the robustness of the results.
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Idioma: Inglés Revista: Immun Ageing Año: 2021 Tipo del documento: Artículo País de afiliación: S12979-021-00237-w

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Idioma: Inglés Revista: Immun Ageing Año: 2021 Tipo del documento: Artículo País de afiliación: S12979-021-00237-w